When conducting large scale inference, such as genome-wide association studies or image analysis, nominal p-values are often adjusted to improve control over the family-wise error rate (FWER).
Introduction
Modern day technology like microarrays, RNA-sequencing, and fMRI Imaging, has given rise to a new era of statistical methods for high-throughput science. These methods are commonly referred to as large-scale inference, and can produce data corresponding to millions of statistical hypotheses for simultaneous testing. However, the repeated application of classical hypothesis testing methods can lead to concerns regarding control over the inflated Family-wise Error Rate (FWER), global Type I Error rate, and reduced statistical power (Efron (2012) ).
Bonferroni adjustments, which provides strict control of the FWER, are highly conservative in the large-scale context and they are often avoided because of the dramatic loss of power that is associated with their use (Sham and Purcell (2014) ). The literature is turning to other pvalues adjustments, such as the Benjamini-Hochberg (B-H) False discovery rate (Fdr) procedure (Benjamini and Hochberg (1995) ), which improves power by relaxing control of the FWER. The FWER can remain inflated, so long as the Fdr remains below a pre-specified threshold. This yields increased power because the FWER inflation is reduced, but not eliminated. Note that it is not possible to control both the FWER and Fdr simultaneously. Both quantities are functions of the per comparison Type I Error rate, so a compromise between must be made.
When the majority of tests are null and Fdr adjustments are warranted, Efron (2012) ad-vocated for replacing the theoretical null with its empirical estimate to improve the operating characteristics of Fdr procedures. This empirical Fdr procedure is an empirical Bayes procedure where the empirical null distribution is estimated from the mixture distribution of null and nonnull test statistics. A more desirable error-rate tradeoff results because the mixture distribution of test statistics does not necessarily follow the theoretical null distribution in large-scale data, often because of a complex correlation structure.
While the use of the empirical null distribution has so far been limited to Fdr computations, this idea is readily propagated to the computation of p-values in large-scale data. Specifically, we propose standardizing p-value or test statistics of interest to the empirical null distribution. Despite the well documented problems with p-values, inference based on them is still more intuitive to applied scientists than inference based on false discovery rates. This approach has the added advantage of limiting the confusion between the inferential roles of Fdr and the p-value. The Fdr measures the tendency of the observed results to be misleading, while the p-value measures the degree to which the data are compatible with the null hypothesis (Blume (2011) ). The former measures the uncertainly of the observed findings, while the latter is the metric of the strength of statistical evidence. We found through our investigations that empirically standardized p-values result in a desirable error-rate compromise between Bonferroni and Fdr methods.
We also observed extreme dependence of p-value and Fdr inference on working model assumptions. A common example is the assumption of a simple or trivially adjusted regression model in GWAS studies. In many cases, the sensitivity of the findings to this assumption was much higher than it was to the choice of the significance cutoff. To address this issue, we propose accounting for model uncertainty by model averaging via bootstrap aggregation (Bagging) when computing p-values or Fdrs. The resulting bagged empirical null (BEN) p-values almost always dramatically altered the rank ordering of significant findings. We also examined simple procedures that selecting findings on the basis of both BEN p-values and bagged model fit statistics. The idea is to favor significant findings from the model that fits the data better. Not surprisingly, this tended to yield reproducible findings more often because the stability of the inferential model is accounted for.
A potential downside to this approach is the additional computation time and knowledge base needed to bag models and compute the empirical null distribution. However, the changes in the p-value ranking were so dramatic in our examples and simulations, that we suggest this step never be skipped. An analysis of the famous Golub Leukemia data, using our proposed BEN p-value approach to rank potential genes of interest, leads us to new discoveries that were confirmed in animal models that had been published before the Golub and others (1999) study was implemented. This provides some external biological confirmation for the adequacy of our new methods.
Background
Large-scale data is often characterized by the simultaneous acquisition of data on many variables or endpoints, in such a manner that the number of observations n is often a magnitude or more less than the number of endpoints N . Genome wide association studies (GWAS), functional magnetic resonance imaging (fMRI), and Tandem mass spectrometry (MS/MS) are some examples of scientific processes that may yield such large data sets. While the science and relevance of these large-scale endeavors has evolved over the last decade, the popular statistical approaches for handling simultaneous testing of many hypothesis -massive multiple comparison adjustmentshas not seen similar growth.
The Bonferroni procedure, popularized in the statistical literature by Dunn (1959) , remains the popular choice in many genetic sub-specialties largely due to its simplicity. For example, the commonly used Bonferroni threshold of 5 × 10 −8 will control the FWER to 0.05 if 1 million gene hypotheses are tested simultaneously (Pe'er and others (2008) ). However, this adjustment is associated with a massive loss in statistical power. The Bonferroni procedure was never intended for these large-scale scenarios where individual hypotheses are of interest (Perneger (1998); Miller (2012) ).
Competitors to the Bonferroni procedure have been considered, with some yielding substantial power gains in small-scale settings (Wright (1992) ). As an alternative, Benjamini and Hochberg (1995) and separately Shaffer (1995) proposed relaxing control of the FWER and instead controlling the two-tailed Global False discovery rate (Remark A of the Supplement elaborates).
Of course, the ranking and selection of top p-values for the purpose of identifying findings as scientifically significant and worthy of further study has seen much debate, e.g. see Sham and Purcell (2014 Importantly, nearly all adjustment procedures including B-H control of the Fdr or control of the two-tailed Global Fdr under the theoretical null, do not alter the p-value ranks; instead they simply adjusts the level at which a given p-value is considered "significant. The lone exception is the local false discovery rate, and this is due to the lack of smoothness of the empirical density estimator. The failure of these methods to change the rankings of signifiant endpoints raises the question of whether these procedures have different discrimination capability or are simply re-calibrations of each other. As we will see, the bagging and use of empirical null p-values does alter the rankings while maintaining error-rate control, which is an exciting advance.
Organization of Paper
The main idea is to use bagged empirical null p-values and bagged model fit criteria to identify interesting and statistically significant findings in large-scale contexts. We compare this new approach to the popular approaches in use today. The proposed methods are applied to a Leukemia microarray data set (Golub and others (1999) 
Materials and Methods
Here we define and describe the computational algorithm for our novel Bagged Empirical Null (BEN) p-values, establish simulations to examine its performance and apply it to the famous Gloub leukemia data set (Golub and others (1999) ).
Leukemia data
The publicly available leukemia data consists of gene expression data for classification of leukemia into two types, Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML), the latter of which has the worse prognosis. females) are available for analyses. The raw data are publicly available online via the 'golubEsets' package in Bioconductor. Gender was missing for 23 patients, and for each simulation missing covariate information was imputed using single imputation and predictive mean matching. As described by Efron (2012) , data were normalized in order to eliminate response disparities among microarrays and reduce the impact of outlying values.
The Empirical Null
P -values and Fdr computations rely on the assumption that the theoretical null density is known.
However, when conducting genome wide studies, this is a strong assumption that is likely false for a significant number of genes or SNPs. Nevertheless, it is highly believable that a very large proportion are null, leading to a situation where the null mixing distribution can be well estimated from the data at hand. As described by Efron (2012) For an individual gene i, the usual null hypothesis is H 0i : gene i is null. The corresponding z-statistic, under normal assumptions, follows a standard normal distribution such that H 0i :
However, by examining the empirical mixing distribution of z i 's, we can assess if the typical theoretical null is supported by the data. We differentiate the individual null densities,
, and non-null densities, f 1 (z i ), for i = 1 . . . N genes. We denote the mixture null comprised
where π 0 and π 1 are the null and non-null prior probabilities (Efron (2012)).
The empirical null can be estimated by central matching or maximum likelihood estimation, both of which rely on the assumption that some central region of the empirical distribution exists where all genes are not differentially expressed (Remark B of the Supplement for details). Empirical null methods essentially accommodate a "blurry" null hypotheses, in which the uninteresting cases can deviate in minor ways from the theoretical null formulation.
Note that variations of the empirical null are possible depending on the desired modeling assumptions. For example, one can assume normality and estimate both the mean and the variance.
Or, alternatively, one could fix the mean at zero and estimate the variance. The latter is intriguing, as it seems natural that empirical null should also be zero centered because the correlation would not affect centering. However, we explored variations like these and found little difference when compared to the classic empirical null algorithms, so the results are not included here.
Model Selection and Bootstrap Aggregation
Misspecification of the underlying model can be a real problem for reliable inference. For example, when testing for differentially expressed genes, a common practice is to perform N t-tests, where
N is equal to the number of genes. This is equivalent to N univariate linear models, each regressing gene expression on disease status. Often, a logistic regression model is more appropriate, since the goal is to use gene expression to predict leukemia status. In addition, the set of models considered ought to be adjusted for potentially confounding effects, allow for nonlinear effects, and possibly include robust standard errors. All of these things will significantly impact the final inference, but they are often ignored in routine applications.
A way to address many of these concerns is to use bootstrap aggregation (bagging) Breiman (1996) . This method averages estimands of interest from a set of bootstrapped models. Bagging is often applied to situations where the estimator heavily depends on the sample, and perturbations of the sample may lead to significant changes in the statistical measure. Bagging has been shown to improve biological inference on gene sets (Jaffe and others (2013) ), however the usefulness of this method has only been investigated for estimating the probability that a significant gene finding will replicate, so our application here is novel.
Algorithm
The algorithm for computing BEN p-values consists of the following steps:
1. Choose the set of generalized linear models appropriate for the statistical question; including potential covariate adjustments, interactions, non-linear effects, and robust standard errors.
2. Resample the data B times, and fit the entire set of models from
Step 1 in each of the B bootstrap resamples, for each of the N genes being tested.
hypothesis test of interest (i.e., z-value corresponding to, say, gene expression in the model).
4. Use the N z-values from each model to estimate the Empirical Null distribution, N (µ, σ).
Standardize the test statistics to the empirical null distribution. Compute p-values and and
Fdrs under the empirical null as usual.
6. For each of the N endpoints, select the model with the 'best' model fit (e.g., best AIC) and save all statistics of interest for that model.
7. Repeat B times.
8. Take the average of the B statistics for each of the N genes.
9. Report the average empirical null p-value and averaged model fit statistic (e.g., AUC).
These are the bagged statistics.
10. Flag genes as significant if they meet a multi-dimensional threshold on the BEN p-value and bagged fit statistic.
2.4.1
Step 3 use the p-value from the chunk test, and then transform back to z-scale in the same manner.
Details on
Step 4: Estimating the Empirical Null There are several ways to 'bag' the empirical null distribution. The most principled approach is described in the algorithm above, where each model is fit, and an empirical null distribution is estimated from the z values obtained from a single model. If there are m models to choose from, m empirical nulls will be estimated, and m*N statistics, will be calculated in total. We call this the principled approach because the underling working model is held fixed across the genes. Then, for each of the N genes, the set of desired statistics is chosen from the model with the 'Best fit' (e.g., lowest AIC). An alternative is this: after the m models are fit, the z-values are selected from the 'Best fit' model, and then a single empirical null is estimated from the N z-values. Here the working model is allowed to vary across the genes. Lastly, one could estimate a single empirical null distribution from the combined m*N z-values across all models. This approach adds a layer of correlation to the mixture distribution but is not favoring the 'best' fit model. These last two approaches to computing the empirical null distribution have the advantage of only one computation cycle, speeding up the algorithm.
There was little difference between the empirical null procedures in practice, and we found that other approaches did not significantly alter the BEN p-value rankings. For this paper, we used the "principled" approach, and the two alternative methods are explored in Remark C of the Supplement since they appear to be viable shortcuts that merit further exploration.
Simulation and Implementation

Pseudo-Simulation
Large-scale data is often defined by its rich and complex correlation structure, which often extends non-uniformly over columns, rows, and clusters. As such, it is very hard to simulate realistic large-scale data from scratch. Because of this, we took a "Pseudo-Simulation" approach. Our idea is to take the subset of Gloub null genes and remove any mean effects via a highly parameterized regression including several covariates and interactions. The matrix of residuals retains the complex correlation structure, upon which we add back fixed effects via an assumed regression model (this is our simulation engine). We refer to this simulation as 'Pseudo' because we are not generating new error structures. In effect, we get a simulation using a real-world error structure and thus retain the complexity of these large-scale data that is often critical to the evaluation of novel methods.
Specifically, we did the following: In the original unchanged leukemia data, fit univariate linear models for each gene, and then took the subset of genes whose p-value associated with the AML/ALL coefficient was greater than 0.3. This resulted in 3172 genes whose gene expressions we assumed have little to no association with leukemia type. We then randomly selected 30 genes within this subset, computed the residuals after regressing over as many effects as we could, and induced 10 genes to have a strong association, 10 genes to have a moderate association, and 10 genes to have a weak association between leukemia type and gene expression.
To selectively adjust certain gene expression levels and leukemia relationships, new expression data was estimated by adding new fitted values, The pseudo-simulated data was then normalized, and the BEN algorithm was implemented.
The pseudo-simulations were conducted under linear regression models because (1) they provide a direction comparison to methods based on single univariate t-statistics, common in the literature and (2) their residuals are well defined when compared to logistic regression. We expect the results would extend to logistic regression, and our primary example uses logistic regression. The following linear models were considered for the BEN algorithm:
Logistic Regression Models Applied to the Leukemia Data
Two separate implementations of the BEN algorithm were performed for the leukemia data using both linear regression and logistic regression. Since the set of logistic models are more appropriate for answering the scientific question at hand, these are the models discussed here.
The linear regression results are included in Remark D of the Supplement.
7128 regression models were fit, and the models included all combinations of the covariates gene expression (continuous), site of sample (peripheral blood vs. bone marrow), and gender (male vs. female). In two of the regression models, gene expression was modeled flexibly using restricted cubic splines, as gene expression does not necessarily have a linear relationship with leukemia type.
The following models were considered for each of the 500 bootstrap aggregations: 
Results
Pseudo-Simulation
Univariate linear regression models were fit for every gene using the manipulated data: E{Gene Expression} i = β 0i +β 1i {Leukemia Type} for i = 1 . . . 3172. The unadjusted, Bonferroni, and Benjamini-Hochberg which is more likely to be close to the correct but unknown model, and this results in more true discoveries.
Note that in the pseudo-simulation the Empirical Null (EN) p-values tended to have more false discoveries than the unadjusted p-values. We expect this to be true if we assume 3142 genes are truly null, then we would expect 157 false discoveries by chance alone, a result in line with the EN p-values. The combination of bagging and empirical null procedures is more likely to select the truly differentially expressed genes (Table 1) . It also has a more desirable FDR/Power tradeoff, and therefore should be preferred over other p-value adjustment techniques. Golub and others (1999) reports 50 top genes (25 genes most differentially expressed in AML patients, and 25 genes most differentially expressed ALL patients). Lee and others (2003) reports the 27 genes which are the best classifiers of ALL vs. AML using a Bayesian variable selection approach. Bø and Jonassen (2002) report the top 50 genes for ALL/AML class separation using their all pairs subset selection procedure. Zhou and others (2004) report the top 20 important genes selected using their proposed Bayesian gene selection algorithm. Tong and Schierz (2011) report the 22 genes selected by their genetic algorithm-neural network. For comparison, we also compare the top 20 smallest univariate logistic regression p-value and the 7 Bonferroni adjusted p-values 0.05 associated with leukemia type.
The BEN algorithm resulted in 22 genes who met the dual criterion of BEN p-value 0.1 and bagged AUC 0.90 (Table 2) . Of this set, the gene with the smallest p-value is M83667 a known transcription factor of the NF-IL6-beta protein. A study by Natsuka and others (1992) , that predates the leukemia study, found there was a drastic increase in expression of NF-IL6 messenger RNA (mRNA) during the differentiation to a macrophage lineage in mouse myeloid leukemia cells using mouse models. The original Golub and others (1999) paper does not report this gene as one of top 50 genes differentially expressed in AML/ALL patients. Lee and others (2003) and Zhou and others (2004) also fail to identify this gene. Given the prior prominence of M83667, which appears to be a major omission. selected by the BEN algorithm 2-dimensional criterion in Table 2. 4.2.4 Visualizing the 2-dimensional criteria We propose using a dual criterion of p-values and model fit statistics (AUC) for selecting a subset of genes for further investigation (Figure 3 ).
Comparison of p-values
Visualizing the relationship between p-values and AUC from the leukemia data makes it clear that even small p-values can have a low corresponding AUC. The AUC cutoff criterion (horizontal dashed lines) could be adjusted up or down to further restrict or grow the set of genes for study.
We have chosen 0.9, but this threshold (or the similar R 2 threshold in Table 1 ) could be selected specifically to choose a subset whose size is feasible for further study. 
Discussion
We have developed a Bagged Empirical Null strategy for obtaining p-values that do not need to be adjusted post-hoc when performing large scale inference. Based on our simulations and examples, combining these p-values with bagged model fit statistics appears to be advantageous as it tends to select truly differentially expressed genes more often than traditional p-value corrections. This direct approach to p-value calculations may be more useful when the goal is to identify the maximum number of truly significant genes, while controlling the FDR and maximizing the power.
Our motivation comes from gene expression microarray data analysis, where the same set of genes does not seem to be reproducible across different experiments of statistical methodologies.
In this unique setting, it is highly impractical to pre-specify a different model for every gene, and so for situations where a large number of tests are to be evaluated (as in genetic and other high-dimensional data), current methodology can benefit from bootstrap aggregating procedures.
We have applied our method to pseudo-simulated gene expression data and the original leukemia data, and have demonstrated that our method is superior by having the most desirable Type I/Type II error tradeoff. A strength of our approach is the ability to consider any set of models (parameters, link function, non-parametric model) during bagging, as well as not being confined to the conventional theoretical null as the testing distribution. By incorporating bootstrapping, model selection, and empirical null procedures, the BEN algorithm has the advantage of using multi-dimensional gene selection metrics, beyond the single adjusted p-value traditionally used. Consequently, the BEN algorithm will lead to more robust and reproducible biological findings.
